Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| endothelial cell | 5 studies | 20% ± 4% | |
| epithelial cell | 5 studies | 30% ± 12% | |
| natural killer cell | 4 studies | 18% ± 3% | |
| B cell | 4 studies | 19% ± 2% | |
| CD16-positive, CD56-dim natural killer cell, human | 3 studies | 18% ± 3% | |
| precursor B cell | 3 studies | 21% ± 2% | |
| ciliated cell | 3 studies | 23% ± 5% | |
| macrophage | 3 studies | 19% ± 2% | |
| GABAergic neuron | 3 studies | 25% ± 6% | |
| glutamatergic neuron | 3 studies | 34% ± 8% | |
| basal cell | 3 studies | 23% ± 5% | |
| neuron | 3 studies | 19% ± 2% | |
| oligodendrocyte | 3 studies | 19% ± 3% | |
| astrocyte | 3 studies | 21% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 800.15 | 1445 / 1445 | 100% | 5.85 | 183 / 183 |
| lung | 100% | 883.75 | 577 / 578 | 100% | 6.17 | 1155 / 1155 |
| breast | 100% | 984.52 | 459 / 459 | 100% | 8.81 | 1116 / 1118 |
| brain | 100% | 716.92 | 2634 / 2642 | 100% | 6.34 | 705 / 705 |
| prostate | 100% | 1073.95 | 245 / 245 | 100% | 6.20 | 500 / 502 |
| uterus | 100% | 1202.83 | 170 / 170 | 99% | 7.56 | 456 / 459 |
| thymus | 100% | 1289.95 | 653 / 653 | 99% | 7.65 | 600 / 605 |
| bladder | 100% | 919.19 | 21 / 21 | 99% | 7.38 | 498 / 504 |
| ovary | 100% | 1068.81 | 180 / 180 | 99% | 6.15 | 424 / 430 |
| pancreas | 100% | 593.68 | 327 / 328 | 99% | 6.42 | 176 / 178 |
| liver | 100% | 645.46 | 226 / 226 | 98% | 5.91 | 399 / 406 |
| stomach | 100% | 718.90 | 359 / 359 | 97% | 5.42 | 276 / 286 |
| intestine | 100% | 935.79 | 966 / 966 | 96% | 5.44 | 507 / 527 |
| adrenal gland | 100% | 931.56 | 258 / 258 | 96% | 5.28 | 221 / 230 |
| skin | 100% | 827.47 | 1809 / 1809 | 96% | 8.34 | 452 / 472 |
| kidney | 100% | 797.21 | 89 / 89 | 93% | 5.09 | 839 / 901 |
| adipose | 100% | 896.87 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 872.52 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 7.32 | 29 / 29 |
| spleen | 100% | 1119.81 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 5.29 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 2.85 | 1 / 1 |
| muscle | 100% | 546.63 | 802 / 803 | 0% | 0 | 0 / 0 |
| heart | 99% | 519.31 | 856 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 88% | 599.43 | 818 / 929 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 79% | 5.11 | 63 / 80 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006974 | Biological process | DNA damage response |
| GO_0006310 | Biological process | DNA recombination |
| GO_0006281 | Biological process | DNA repair |
| GO_0006397 | Biological process | mRNA processing |
| GO_0006260 | Biological process | DNA replication |
| GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
| GO_0016363 | Cellular component | nuclear matrix |
| GO_0032991 | Cellular component | protein-containing complex |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0003690 | Molecular function | double-stranded DNA binding |
| GO_0003677 | Molecular function | DNA binding |
| GO_0005515 | Molecular function | protein binding |
| GO_0046872 | Molecular function | metal ion binding |
| GO_0003723 | Molecular function | RNA binding |
| Gene name | KIN |
| Protein name | Kin17 DNA and RNA binding protein DNA/RNA-binding protein KIN17 (Binding to curved DNA) (KIN, antigenic determinant of recA protein homolog) |
| Synonyms | BTCD KIN17 |
| Description | FUNCTION: Involved in DNA replication and the cellular response to DNA damage. May participate in DNA replication factories and create a bridge between DNA replication and repair mediated by high molecular weight complexes. May play a role in illegitimate recombination and regulation of gene expression. May participate in mRNA processing. Binds, in vitro, to double-stranded DNA. Also shown to bind preferentially to curved DNA in vitro and in vivo (By similarity). Binds via its C-terminal domain to RNA in vitro. . |
| Accessions | ENST00000379562.9 [O60870-1] O60870 ENST00000498098.1 S4R357 |